OPG is Associated with Thyroid Nodule Development in Type 2 Diabetes

Overview

Journal J Clin Lab Anal

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
Pathology

Date 2022 Jul 23

PMID 35870175

Authors

Dazhi Huang

Yixin Niu

Weiwei Zhang

Xiaoyong Li

Ning Lin

Zhen Yang

Li Qin

Qing Su

Hui Ran

Hongmei Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Thyroid nodule prevalence is increasing lately, especially in diabetes, but the mechanism of which is not clear. In this study, we investigated if osteoprotegerin (OPG) is involved in the pathogenesis of thyroid nodules in diabetes.

Methods: A total of 7568 individuals with detailed information and ultrasound examination results were studied for the prevalence of thyroid nodules. Among them, 1883 were with type 2 diabetes and 5685 were non-diabetic. Then, 1120 individuals were randomly selected for the measurement of OPG. Diabetic rats were made by feeding a high-fat-high-fructose diet for 28 weeks. Rats fed with a normal diet were as controls. Fresh thyroid tissues were obtained and fixed, dehydrated, and embedded in paraffin for hematoxylin-eosin staining and observing pathological changes. qPCR and western blot were used to detect OPG expression in rat thyroid tissues.

Results: We found that HbA1c is an independent risk factor for thyroid nodules (Exp [β] = 1.158, p < 0.001). The prevalence of thyroid nodules in type 2 diabetes was higher than that in non-diabetes (53.9% vs. 46.7%, p < 0.001). Serum OPG levels were significantly elevated in the diabetes group than in the non-diabetes group (3160.17 pg/ml vs. 2819.39 pg/ml, p < 0.01). The expression of OPG increased significantly in the thyroid tissues of diabetic rats.

Conclusion: Osteoprotegerin may be associated with thyroid nodule development in diabetes.

Citing Articles

Unveiling the link between ACR TI-RADS grading and Bethesda score of thyroid nodules in diabetic patients: A comprehensive analysis.

Wang Y, Chen X, Chen Y, Xie F, Wang Z, Mao R Biomol Biomed. 2024; 24(6):1717-1725.

PMID: 38889391 PMC: 11496854. DOI: 10.17305/bb.2024.10670.

OPG is associated with thyroid nodule development in type 2 diabetes.

Huang D, Niu Y, Zhang W, Li X, Lin N, Yang Z J Clin Lab Anal. 2022; 36(9):e24615.

PMID: 35870175 PMC: 9459264. DOI: 10.1002/jcla.24615.

References

Goswami S, Sharma-Walia N . Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis. BMC Cancer. 2015; 15:935. PMC: 4660791. DOI: 10.1186/s12885-015-1837-1. View

Polyzos S, Kita M, Efstathiadou Z, Poulakos P, Slavakis A, Sofianou D . Serum thyrotropin concentration as a biochemical predictor of thyroid malignancy in patients presenting with thyroid nodules. J Cancer Res Clin Oncol. 2008; 134(9):953-60. DOI: 10.1007/s00432-008-0373-7. View

Huang D, Niu Y, Zhang W, Li X, Lin N, Yang Z . OPG is associated with thyroid nodule development in type 2 diabetes. J Clin Lab Anal. 2022; 36(9):e24615. PMC: 9459264. DOI: 10.1002/jcla.24615. View

Heymann M, Riet A, Le Goff B, Battaglia S, Paineau J, Heymann D . OPG, RANK and RANK ligand expression in thyroid lesions. Regul Pept. 2008; 148(1-3):46-53. DOI: 10.1016/j.regpep.2008.02.004. View

Ayina Ayina C, Sobngwi E, Essouma M, Noubiap J, Boudou P, Ngoa L . Osteoprotegerin in relation to insulin resistance and blood lipids in sub-Saharan African women with and without abdominal obesity. Diabetol Metab Syndr. 2015; 7:47. PMC: 4450452. DOI: 10.1186/s13098-015-0042-3. View

Baudhuin M, Duplomb L, Velasco C, Fortun Y, Heymann D, Padrines M . Key roles of the OPG-RANK-RANKL system in bone oncology. Expert Rev Anticancer Ther. 2007; 7(2):221-32. DOI: 10.1586/14737140.7.2.221. View

Wong R, Farrell S, Grossmann M . Thyroid nodules: diagnosis and management. Med J Aust. 2018; 209(2):92-98. DOI: 10.5694/mja17.01204. View

Bernardi S, Fabris B, Thomas M, Toffoli B, Tikellis C, Candido R . Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. Mol Cell Endocrinol. 2014; 394(1-2):13-20. DOI: 10.1016/j.mce.2014.06.004. View

Brandt F, Thvilum M, Almind D, Christensen K, Green A, Hegedus L . Morbidity before and after the diagnosis of hyperthyroidism: a nationwide register-based study. PLoS One. 2013; 8(6):e66711. PMC: 3688572. DOI: 10.1371/journal.pone.0066711. View

10.

Walsh J . Managing thyroid disease in general practice. Med J Aust. 2016; 205(4):179-84. DOI: 10.5694/mja16.00545. View

11.

Diez J, Iglesias P . An analysis of the relative risk for goitre in euthyroid patients with type 2 diabetes. Clin Endocrinol (Oxf). 2013; 80(3):356-61. DOI: 10.1111/cen.12169. View

12.

Xu W, Chen Z, Li N, Liu H, Huo L, Huang Y . Relationship of anthropometric measurements to thyroid nodules in a Chinese population. BMJ Open. 2015; 5(12):e008452. PMC: 4691709. DOI: 10.1136/bmjopen-2015-008452. View

13.

Duan P, Yang M, Wei M, Liu J, Tu P . Serum Osteoprotegerin Is a Potential Biomarker of Insulin Resistance in Chinese Postmenopausal Women with Prediabetes and Type 2 Diabetes. Int J Endocrinol. 2017; 2017:8724869. PMC: 5308197. DOI: 10.1155/2017/8724869. View

14.

Heidari Z, Mashhadi M, Nosratzehi S . Insulin Resistance in Patients with Benign Thyroid Nodules. Arch Iran Med. 2015; 18(9):572-6. DOI: 0151809/AIM.005. View

15.

Sood S, Balasubramanian S, Higham S, Fernando M, Harrison B . Osteoprotegerin (OPG) and related proteins (RANK, RANKL and TRAIL) in thyroid disease. World J Surg. 2011; 35(9):1984-92. DOI: 10.1007/s00268-011-1185-5. View

16.

Zhang H, Feng Q, Niu Y, Su Q, Wang X . Thyroid Nodules in Type 2 Diabetes Mellitus. Curr Med Sci. 2019; 39(4):576-581. DOI: 10.1007/s11596-019-2076-5. View

17.

Tsilidis K, Kasimis J, Lopez D, Ntzani E, Ioannidis J . Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015; 350:g7607. DOI: 10.1136/bmj.g7607. View

18.

Suliburska J, Bogdanski P, Gajewska E, Kalmus G, Sobieska M, Samborski W . The association of insulin resistance with serum osteoprotegerin in obese adolescents. J Physiol Biochem. 2013; 69(4):847-53. DOI: 10.1007/s13105-013-0261-8. View

19.

Niu Y, Yang Z, Li X, Zhang W, Lu S, Zhang H . Association of osteoprotegerin with impaired glucose regulation and microalbuminuria: the REACTION study. BMC Endocr Disord. 2015; 15:75. PMC: 4665817. DOI: 10.1186/s12902-015-0067-5. View

20.

Ning G . Risk Evaluation of cAncers in Chinese diabeTic Individuals: a lONgitudinal (REACTION) study. J Diabetes. 2012; 4(2):172-3. DOI: 10.1111/j.1753-0407.2012.00182.x. View